IP Library › Granted Patent US 7,521,591
Granted Patent B2
US 7,521,591 · App. 10/696,671 · Granted Apr 21, 2009

Transgenic chickens that lay eggs containing exogenous proteins

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,521,591
App. No.
10/696,671
Granted
Apr 21, 2009
Kind
B2
Abstract

This invention provides eggs which contain exogenous proteins. The invention further provides transgenic chickens which express exogenous sequences in their oviducts, and vectors and methods for the stable introduction of exogenous nucleic acid sequences into the genome of a bird for expressing said exogenous sequences to alter the phenotype of the bird or to produce desired proteins.

Claims (46)

1. A germ-line transgenic chicken whose genome contains a transgene introduced by a replication-deficient retroviral vector which lays an egg containing an exogenous protein encoded by the transgene wherein the exogenous protein is produced in the transgene chicken oviduct at a detectable level.

2. A transgenic chicken whose genome contains a transgene introduced by a replication-deficient retroviral vector which lays an egg containing a pharmaceutical protein encoded by the transgene wherein the pharmaceutical protein is produced in the transgenic chicken oviduct at a detectable level and is exogenous to the egg.

3. The transgenic chicken of claim 2 wherein the pharmaceutical protein is present in egg white of the egg laid by the transgenic chicken.

4. A germ-line transgenic chicken whose genome contains a transgene introduced by a replication-deficient retroviral vector which lays an egg containing egg white comprising a protein exogenous to the egg white, wherein the protein exogenous to the egg white is encoded by the transgene and is produced in the transgenic chicken oviduct at a detectable level.

5. The germ-line transgenic chicken of claim 4 wherein the protein is selected from the group consisting of interferon, G-CSF, erythropoietin, GM-CSF, antitrypsin, antithrombin III, collagen, factors VIII, IX, X, fibrinogen, insulin, protein C, tissue-type plasminogen activator, somatotrophin, cytokine, antibody, human growth hormone, immunotoxin and chymotrypsin.

6. A transgenic chicken whose genome contains a transgene introduced by a replication-deficient retroviral vector which lays an egg containing a cytokine encoded by the transgene wherein the cytokine is produced in the transgenic chicken oviduct at a detectable level and is exogenous to the chicken.

7. The transgenic chicken of claim 6 wherein the cytokine is interferon.

8. The transgenic chicken of claim 6 wherein the cytokine is GM-CSF.

9. The transgenic chicken of claim 6 wherein the cytokine is G-CSF.

10. The transgenic chicken of claim 6 wherein the cytokine is erythropoietin.

11. A method comprising purifying an exogenous protein from an egg of a transgenic chicken whose genome contains a transgene introduced by a replication-deficient retroviral vector which lays the egg containing the exogenous protein at a detectable level wherein the exogenous protein is encoded by the transgene.

12. The method of claim 11 wherein the exogenous protein is interferon.

13. The method of claim 11 wherein the exogenous protein is G-CSF.

14. The method of claim 11 wherein the exogenous protein is erythropoietin.

15. The method of claim 11 wherein the exogenous protein is GM-CSF.

16. The method of claim 11 wherein the exogenous protein is antitrypsin.

17. The method of claim 11 wherein the exogenous protein is antithrombin III.

18. The method of claim 11 wherein the exogenous protein is collagen.

19. The method of claim 11 wherein the exogenous protein is selected from the group consisting of factor VIII, factor IX and factor X.

20. The method of claim 11 wherein the exogenous protein is fibrinogen.

21. The method of claim 11 wherein the exogenous protein is insulin.

22. The method of claim 11 wherein the exogenous protein is lactoferrin.

23. The method of claim 11 wherein the exogenous protein is protein C.

24. The method of claim 11 wherein the exogenous protein is tissue-type plasminogen activator.

25. The method of claim 11 wherein the exogenous protein is somatotrophin.

26. The method of claim 11 wherein the exogenous protein is a cytokine.

27. The method of claim 11 wherein the exogenous protein is an antibody.

28. The method of claim 11 wherein the exogenous protein is human growth hormone.

29. The method of claim 11 wherein the exogenous protein is chymotrypsin.

30. The germ-line transgenic chicken of claim 1 wherein the exogenous protein is erythropoietin.

31. The germ-line transgenic chicken of claim 1 wherein the exogenous protein is G-CSF.

32. The germ-line transgenic chicken of claim 1 wherein the exogenous protein is interferon.

33. The germ-line transgenic chicken of claim 1 wherein the exogenous protein is GM-CSF.

34. The germ-line transgenic chicken of claim 1 wherein the exogenous protein is antitrypsin.

35. The germ-line transgenic chicken of claim 1 wherein the exogenous protein is antithrombin III.

36. The germ-line transgenic chicken of claim 1 wherein the exogenous protein is collagen.

37. The germ-Line transgenic chicken of claim 1 wherein the exogenous protein is selected from the group consisting of factor VIII, factor IX and factor X.

38. The germ-line transgenic chicken of claim 1 wherein the exogenous protein is fibrinogen.

39. The germ-line transgenic chicken of claim 1 wherein the exogenous protein is insulin.

40. The germ-line transgenic chicken of claim 1 wherein the exogenous protein is lactoferrin.

41. The germ-line transgenic chicken of claim 1 wherein the exogenous protein is protein C.

42. The germ-line transgenic chicken of claim 1 wherein the exogenous protein is tissue-type plasminogen activator.

43. The germ-line transgenic chicken of claim 1 wherein the exogenous protein is somatotrophin.

44. The germ-line transgenic chicken of claim 1 wherein the exogenous protein is an antibody.

45. The germ-line transgenic chicken of claim 1 wherein the exogenous protein is human growth hormone.

46. The germ-line transgenic chicken of claim 1 wherein the exogenous protein is chymotrypsin.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2016
From: GALAXY MERGER SUB LLC
To: ALEXION PHARMA LLC
Reel/Frame 037872/0121 →
CHANGE OF NAME Recorded Jan 30, 2009
From: AVIGENICS, INC.
To: SYNAGEVA BIOPHARMA CORP.
Reel/Frame 022177/0940 →